Kodak's Adjacency Bets Weren't Bad Deals. They Were Brilliant Deals at the Worst Possible Time.

In January 1988, the most famous name in photography wrote a check for a company that made aspirin and Lysol. Kodak paid $89.50 a share — roughly $5.1 billion — for Sterling Drug, and it did so not because it had a thesis about pharmaceuticals but because Sterling was being chased by Hoffmann-La Roche and needed someone to rescue it.⁴ Kodak volunteered. The yellow-box film company was now, suddenly, in the drug business. And buried in a Rochester lab, a thirteen-year-old patent for a toaster-sized device that captured pictures with no film at all sat doing nothing in particular.² The company chose the deal that would make money and ignored the one that would matter.

The official story is that Kodak failed because it loved film too much to embrace digital. That story is half true and entirely misleading. The more uncomfortable version is this: Kodak was financially smart about its adjacencies and strategically asleep about its core. It made money getting into pharma and made more money getting out — and the whole time, the clock on its actual business was running.

The pharma bet was an arbitrage wearing a strategy costume

Strip away the press-release language about 'diversification' and the Sterling deal looks like what it was: white-knight arbitrage. A drug company in play, a deep-pocketed buyer willing to overpay to keep it out of a rival's hands, and a 'strategic rationale' that reads, in retrospect, as assembled around a deal that started as a rescue.⁴ There were tidy-sounding synergies on paper — Kodak knew chemistry, drugs are chemistry — but in practice the businesses shared almost nothing operationally — selling Ektachrome to a drugstore and shepherding a compound through FDA trials are not adjacent skills. They are different industries that happen to use beakers.

Here is the part the cautionary-tale version always omits: the trade worked, on its own terms. Six years later, in 1994, Kodak dismantled Sterling and sold it for parts to buyers who wanted the pieces more than Kodak ever had. The pharma operation went to Sanofi for $1.675 billion, the consumer-health business to SmithKline Beecham for $2.925 billion, the Clinical Diagnostics Division to Johnson & Johnson for $1.008 billion, and the household-products line to Reckitt & Colman for $1.55 billion — over $7 billion in gross proceeds against a $5.1 billion cost.⁵ As a financial maneuver, it was a winner. As a use of the only resource a turnaround cannot replace — the attention of its best people during a narrow window — it was a catastrophe.

The chemical business it was right to let go

The other big adjacency is the inverse case, and it's worth holding up beside pharma because it shows Kodak could read its own balance sheet clearly. Eastman Chemical was born in 1920 as a captive supplier — a way to guarantee Kodak the raw materials its film needed.⁷ For seventy years it did exactly that, then quietly outgrew it. By the early 1990s, Kodak accounted for less than 10 percent of Eastman's sales; the supplier had become a real chemical company with its own customers and its own destiny.⁷ So Kodak did the disciplined thing: it announced the spin-off on June 15, 1993, completed it on December 31, 1993, loaded Eastman with $1.8 billion of new debt, kept no equity stake, and let it walk.⁶ That was correct. A captive supplier that sells you a rounding error of its output is not a strategy; it's a distraction with a logo.

Notice the pattern across both moves. Pharma and chemicals were each, in the end, financial decisions — buy to block a raider, spin off to free trapped value. Kodak treated its portfolio like a portfolio. The trouble is that a company in the path of a technology shift cannot afford to be primarily a capital allocator. It has to be an operator, obsessed, on the thing that is about to be disrupted. Kodak spent 1988 to 1994 being a clever investor in everything except the future of pictures.

The patent that was never really buried

And what of the famous suppressed invention? It is the load-bearing beam of the Kodak legend, and it doesn't hold weight. Steven Sasson's prototype did take its first digital photograph in December 1975 — a 100-by-100-pixel image, written to cassette tape, that took 23 seconds to record.² The patent (US 4,131,919, with Sasson and Gareth Lloyd) was filed on May 20, 1977 and granted on December 26, 1978 — not the grant year of 1977 that retellings insist upon.⁹ But the tidy story that Kodak hid the camera to protect film is, per Snopes and the primary record, an oversimplification: there was no consumer market for a toaster-sized device in 1975, and Kodak kept developing digital technology afterward.³ The real failure wasn't a conspiracy to bury the future. It was something more ordinary and more damning — a company that knew the future was coming and chose, year after year, to spend its energy elsewhere.

Didn't the adjacencies have nothing to do with the bankruptcy?

The fair objection is a strong one: by the time Kodak filed Chapter 11 on January 19, 2012, the pharma and chemical bets were ancient history — pharma exited in 1994, chemicals spun off in 1993.⁸ The immediate causes of the bankruptcy were the collapse of consumer film revenue and an attempt to monetize its digital patent portfolio that yielded a fraction of what Kodak had counted on — the roughly 1,700 digital patents it hoped would fetch billions sold for just $94 million — not a drug company it hadn't owned in eighteen years.¹⁰ All true. The adjacencies did not push Kodak off the cliff. But the cliff is not the point — the path to it is. Strategy isn't bankrupted in the year of the filing; it's bankrupted in the years when the disruption is small enough to ignore and a clever financial deal is available instead. Kodak's 1988-to-1994 window was precisely that period. The adjacencies didn't cause the crash. They consumed the runway that might have prevented it — and that is a quieter, more common, and far more dangerous way for a company to lose.

Kodak knew chemistry, so it dabbled in drugs. Kodak owned a chemical company, so it minded it for seventy years and then sold it well. On both counts the bookkeeping is clean — money in, money out, a small profit, a tidy exit. What the bookkeeping never recorded was the picture Sasson took in a Rochester lab in 1975, and the decade afterward when the company that owned the future of photography was busy being a competent investor in everything but. The lesson isn't that Kodak loved film. It's that a great company can make every individual deal pay and still spend the one resource it can never recover — attention — on the wrong fight entirely.